Trademark: 86622073
Word
THERADIGM
Status
Dead
Status Code
606
Status Date
Monday, June 24, 2019
Serial Number
86622073
Mark Type
4000
Filing Date
Thursday, May 7, 2015
Published for Opposition
Tuesday, March 29, 2016
Abandoned Date
Monday, June 24, 2019

Trademark Owner History
COGNATE BIOSERVICES, INC. - 1st New Owner After Publication
Theradigm, Inc. - Owner At Publication

Classifications
1 Biologics, namely cells and cell lines for scientific and research use in the development, testing and manufacture of therapeutics; Biologics, namely cells and cell lines for scientific and research use in the production of biologic substances, including growth factors and proteins; Biologics, namely cells and cell lines for scientific and research use for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, bone Marrow Stromal Cells (BMSCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, bone Marrow Stromal Cells (BMSCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, bone Marrow Stromal Cells (BMSCs) for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for the testing of chemical substances
5 Biologics, namely cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Bone Marrow Stromal Cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Growth factors for use as medicinal products, namely, cell growth media for growing cells for medical or clinical use; Proteins for use as medicinal products, namely, protein arrays for medical diagnosis purposes; Peptides for use as medicinal products, namely, synthetic peptides for the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; Clinical medical reagents, namely, small molecules for use as medicinal products; Clinical medical reagents, namely, telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of Central Nervous System (CNS) disorders, de-myelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, peripheral neural disorders, autism, Multiple Sclerosis (MS), and MS-like diseases with the following symptoms: cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the Central Nervous System (CNS), namely stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, and autism
40 Manufacturing of biologics, cells, scaffolds and matrices, and related biological materials
42 Pharmaceutical research and development services; Biological research and development services; Medical research and development services in the field of regenerative medicine and immunotherapies; Medical and pharmaceutical consultation and research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical and pharmaceutical consultation in the field of Central Nervous System (CNS) disorders; Medical and pharmaceutical consultation in the field of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, de myelinating disorders, auto-immune disorders, peripheral neural disorders, and autism
44 Medical testing for diagnostic or treatment purposes; Medical treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, and heart and vasculature disorders; Medical treatment of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical treatment of Central Nervous System (CNS) disorders; Medical treatment of stroke, spinal cord injury, brain injury, brain tumours, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical treatment, namely, cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, de myelinating disorders, auto-immune disorders, peripheral neural disorders, and autism

Trademark Events
Jun 24, 2019
Abandonment Notice E-Mailed - No Use Statement Filed
Jun 24, 2019
Abandonment - No Use Statement Filed
Nov 27, 2018
Notice Of Approval Of Extension Request E-Mailed
Nov 26, 2018
Extension 5 Granted
Nov 15, 2018
Extension 5 Filed
Nov 26, 2018
Case Assigned To Intent To Use Paralegal
Nov 15, 2018
Teas Extension Received
May 11, 2018
Notice Of Approval Of Extension Request E-Mailed
May 9, 2018
Extension 4 Granted
May 9, 2018
Extension 4 Filed
May 9, 2018
Teas Extension Received
Nov 24, 2017
Notice Of Approval Of Extension Request E-Mailed
Nov 22, 2017
Extension 3 Granted
Nov 22, 2017
Extension 3 Filed
Nov 22, 2017
Teas Extension Received
May 25, 2017
Notice Of Approval Of Extension Request E-Mailed
May 23, 2017
Extension 2 Granted
May 23, 2017
Extension 2 Filed
May 23, 2017
Teas Extension Received
Nov 23, 2016
Notice Of Approval Of Extension Request E-Mailed
Nov 21, 2016
Extension 1 Granted
Nov 21, 2016
Extension 1 Filed
Nov 21, 2016
Teas Extension Received
Nov 21, 2016
Attorney/Dom.Rep.Revoked And/Or Appointed
Nov 21, 2016
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 24, 2016
Noa E-Mailed - Sou Required From Applicant
Apr 20, 2016
Automatic Update Of Assignment Of Ownership
Mar 29, 2016
Official Gazette Publication Confirmation E-Mailed
Mar 29, 2016
Published For Opposition
Mar 9, 2016
Notification Of Notice Of Publication E-Mailed
Feb 20, 2016
Approved For Pub - Principal Register
Feb 20, 2016
Teas/Email Correspondence Entered
Feb 19, 2016
Correspondence Received In Law Office
Feb 19, 2016
Teas Response To Office Action Received
Aug 24, 2015
Notification Of Non-Final Action E-Mailed
Aug 24, 2015
Non-Final Action E-Mailed
Aug 24, 2015
Non-Final Action Written
Aug 18, 2015
Assigned To Examiner
May 15, 2015
New Application Office Supplied Data Entered In Tram
May 11, 2015
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24